Targeting the cell-cycle machinery for cancer therapy
Trends in Cell Biology · 2026-04 · 36 (4) · 312-325
DOI: 10.1016/j.tcb.2025.08.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cell Biology, 2026-04. Verfasst von Yunhua Peng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; School of Life Science and Technology, Xi'an Jiao…. Hauptthemen laut MEDLINE: Neoplasms, Cell Cycle, Molecular Targeted Therapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: National Institutes of Health, National Natural Science Foundation of China, National Cancer Center.
Abstract (Originalsprache)
The cell cycle is governed by tightly regulated checkpoints and proteogenomic oscillations that ensure genomic fidelity during cell proliferation. Dysregulation of the cell cycle can drive oncogenic transformation, and this positions it as a pivotal target in precision oncology. Recent advances reveal how proteomic and post-translational dynamics orchestrate cell-cycle phase transitions that are aberrantly disrupted in cancers. Therapeutic targeting of the CDK4/6 represents a cornerstone of cancer therapy, but resistance mechanisms limit its clinical efficacy. Emerging strategies such as targeted protein degradation, synthetic lethality, and combination immunotherapies further expand the therapeutic window. These innovations, coupled with biomarker-driven precision medicine, exploit cell-cycle vulnerabilities and transform them into an active tool to combat human cancers more effectively. This review highlights emerging mechanistic insights underlying tumorigenesis driven by an aberrant cell cycle and proposes potential therapeutics aimed at cell-cycle machinery-relevant targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China.
- Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
- Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong Univer…
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: wwei2@bidmc.harvard.edu.
Förderung
- National Institutes of Health
- National Natural Science Foundation of China
- National Cancer Center
Zitieren
APA
Peng, Y., Liu, J., Inuzuka, H., Liu, J., & Wei, W. (2026). Targeting the cell-cycle machinery for cancer therapy. Trends in Cell Biology, 36(4), 312-325. https://doi.org/10.1016/j.tcb.2025.08.008
Vancouver
Peng Y, Liu J, Inuzuka H, Liu J, Wei W. Targeting the cell-cycle machinery for cancer therapy. Trends in Cell Biology. 2026;36(4):312-325. doi:10.1016/j.tcb.2025.08.008
BibTeX
@article{Peng2026,
author = {Peng, Yunhua and Liu, Jiejing and Inuzuka, Hiroyuki and Liu, Jing and Wei, Wenyi},
title = {Targeting the cell-cycle machinery for cancer therapy},
journal = {Trends in Cell Biology},
year = {2026},
volume = {36},
number = {4},
pages = {312--325},
doi = {10.1016/j.tcb.2025.08.008}
}
EUVIMED